Omega Therapeutics Announces Board Restructuring and Appointments
I'm PortAI, I can summarize articles.
Omega Therapeutics announced a board restructuring, with Ravi Mehrotra, Ph.D. and Robert L. Rosiello resigning from the Board of Directors on January 22, 2025. Jeffrey T. Varsalone was appointed as a Class I director on January 24, 2025, while Richard Kender was moved from Class III to Class II to rebalance the board. The company's current market cap is $28.18M, with a year-to-date price performance of -43.35%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments